Results 171 to 180 of about 68,762 (185)

MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles

Nature Reviews Drug Discovery, 2012
Eva Van Rooij, Eric N. Olson
exaly  

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Lancet, The, 2019
Stephen Wiviott, Itamar Raz, Marc P Bonaca   +2 more
exaly  

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Lancet, The, 2019
Hertzel C Gerstein, Helen Colhoun, Gilles R Dagenais   +2 more
exaly  

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Lancet, The, 2018
Adrian F Hernandez, Jennifer B Green, Lawrence A Leiter   +2 more
exaly  

Microbial modulation of cardiovascular disease

Nature Reviews Microbiology, 2018
J Mark Brown, Stanley L Hazen
exaly  

Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?

Kidney International Supplements, 2011
Kitty J Jager, Bengt Lindholm, Andrzej Więcek   +2 more
exaly  

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

Lancet, The, 2013
Ron T Gansevoort, Ricardo C Correa-Rotter, Tazeen Hasan Jafar   +2 more
exaly  

Therapeutic implications of the gender-specific aspects of cardiovascular disease

Nature Reviews Drug Discovery, 2006
Vera Regitz-Zagrosek
exaly  

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lancet, The, 2002
Suzanne Oparil
exaly  

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

Nature Reviews Drug Discovery, 2009
John D Imig, Bruce D Hammock
exaly